Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease
Stefania Grimaudo, Rosaria Maria Pipitone, Grazia Pennisi, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 4, pp. 935-944.e3
Open Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆
Quentin M. Anstee, Rebecca Darlay, Simon Cockell, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 3, pp. 505-515
Open Access | Times Cited: 375
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels
Molecular Metabolism (2020) Vol. 42, pp. 101092-101092
Open Access | Times Cited: 361
Update on NAFLD genetics: From new variants to the clinic
Eric Trépo, Luca Valenti
Journal of Hepatology (2020) Vol. 72, Iss. 6, pp. 1196-1209
Open Access | Times Cited: 313
Limitations of non-invasive tests for assessment of liver fibrosis
Keyur Patel, Giada Sebastiani
JHEP Reports (2020) Vol. 2, Iss. 2, pp. 100067-100067
Open Access | Times Cited: 226
Challenges and opportunities in NASH drug development
Stephen A. Harrison, Alina M. Allen, Julie Dubourg, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 562-573
Closed Access | Times Cited: 194
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Michelle T. Long, Mazen Noureddin, Joseph K. Lim
Gastroenterology (2022) Vol. 163, Iss. 3, pp. 764-774.e1
Open Access | Times Cited: 178
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Stefano Romeo, Arun J. Sanyal, Luca Valenti
Cell Metabolism (2020) Vol. 31, Iss. 1, pp. 35-45
Open Access | Times Cited: 173
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression
Lorenzo A. Orci, Marco Sanduzzi‐Zamparelli, Berta Caballol, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 2, pp. 283-292.e10
Open Access | Times Cited: 160
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
Christian L. Horn, Amilcar Morales, Christopher E. Savard, et al.
Hepatology Communications (2021) Vol. 6, Iss. 1, pp. 12-35
Open Access | Times Cited: 148
NAFLD‐related hepatocellular carcinoma: The growing challenge
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison
Hepatology (2022) Vol. 77, Iss. 1, pp. 323-338
Open Access | Times Cited: 148
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease
Salvatore Petta, Giada Sebastiani, Mauro Viganò, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 4, pp. 806-815.e5
Open Access | Times Cited: 146
Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis
Björn Carlsson, Daniel Lindén, Gabriella Brolén, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 12, pp. 1305-1320
Open Access | Times Cited: 137
Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives
Szu-Yi Liu, I‐Ting Tsai, Yin-Chou Hsu
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5170-5170
Open Access | Times Cited: 102
MAFLD: a multisystem disease
Rosaria Maria Pipitone, Carlo Ciccioli, Giuseppe Infantino, et al.
Therapeutic Advances in Endocrinology and Metabolism (2023) Vol. 14
Open Access | Times Cited: 97
PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis
Vincent Chen, Antonino Oliveri, Matthew J. Miller, et al.
Gastroenterology (2023) Vol. 164, Iss. 6, pp. 966-977.e17
Closed Access | Times Cited: 55
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
James A. Thomas, Bradley J. Kendall, Hashem B. El‐Serag, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 2, pp. 159-169
Closed Access | Times Cited: 41
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
Nikolaos Perakakis, Konstantinos Stefanakis, Christos S. Mantzoros
Metabolism (2020) Vol. 111, pp. 154320-154320
Open Access | Times Cited: 121
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
K. Teo, Kushala Abeysekera, Leon A. Adams, et al.
Journal of Hepatology (2020) Vol. 74, Iss. 1, pp. 20-30
Open Access | Times Cited: 107
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Elke Roeb, Ali Canbay, Frank Tacke, et al.
Zeitschrift für Gastroenterologie (2022) Vol. 60, Iss. 09, pp. 1346-1421
Open Access | Times Cited: 52
Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases
Hwang Sik Shin, Baek Gyu Jun, Sang‐Wook Yi
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 773-789
Open Access | Times Cited: 49
Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches
Eirini Martinou, Marinos Pericleous, Irena Stefanova, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 407-407
Open Access | Times Cited: 45
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
Kiarash Riazi, Mark G. Swain, Stephen E. Congly, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4556-4556
Open Access | Times Cited: 42
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
Amedeo Lonardo, Alessandro Mantovani, Salvatore Petta, et al.
Nature Reviews Endocrinology (2022) Vol. 18, Iss. 10, pp. 638-650
Closed Access | Times Cited: 41
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
Chiara Rosso, Gian Paolo Caviglia, Giovanni Birolo, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 13, pp. 3314-3321.e3
Open Access | Times Cited: 31
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease
Naga Chalasani, Eduardo Vilar‐Gómez, Rohit Loomba, et al.
Hepatology (2024) Vol. 80, Iss. 5, pp. 1212-1226
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top